WO2008089403A2 - Oligosaccharides comprising an aminooxy group and conjugates thereof - Google Patents
Oligosaccharides comprising an aminooxy group and conjugates thereof Download PDFInfo
- Publication number
- WO2008089403A2 WO2008089403A2 PCT/US2008/051429 US2008051429W WO2008089403A2 WO 2008089403 A2 WO2008089403 A2 WO 2008089403A2 US 2008051429 W US2008051429 W US 2008051429W WO 2008089403 A2 WO2008089403 A2 WO 2008089403A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oligosaccharide
- group
- aminooxy
- chosen
- reactive group
- Prior art date
Links
- 229920001542 oligosaccharide Polymers 0.000 title claims abstract description 196
- 150000002482 oligosaccharides Chemical class 0.000 title claims abstract description 195
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 103
- 108090000288 Glycoproteins Proteins 0.000 claims abstract description 32
- 102000003886 Glycoproteins Human genes 0.000 claims abstract description 32
- 230000008878 coupling Effects 0.000 claims abstract description 25
- 238000010168 coupling process Methods 0.000 claims abstract description 25
- 238000005859 coupling reaction Methods 0.000 claims abstract description 25
- 208000015439 Lysosomal storage disease Diseases 0.000 claims abstract description 23
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- -1 aminooxy compound Chemical class 0.000 claims description 103
- 108090000623 proteins and genes Proteins 0.000 claims description 48
- 102000004169 proteins and genes Human genes 0.000 claims description 48
- 125000006239 protecting group Chemical group 0.000 claims description 35
- 102000004190 Enzymes Human genes 0.000 claims description 28
- 108090000790 Enzymes Proteins 0.000 claims description 28
- 230000002132 lysosomal effect Effects 0.000 claims description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
- 150000001875 compounds Chemical class 0.000 claims description 21
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 19
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical group CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 18
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 17
- 150000002148 esters Chemical class 0.000 claims description 16
- 239000003054 catalyst Substances 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 102000005840 alpha-Galactosidase Human genes 0.000 claims description 12
- 108010030291 alpha-Galactosidase Proteins 0.000 claims description 12
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 108010028144 alpha-Glucosidases Proteins 0.000 claims description 10
- 125000004104 aryloxy group Chemical group 0.000 claims description 10
- 125000003277 amino group Chemical group 0.000 claims description 9
- 125000003342 alkenyl group Chemical group 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000000304 alkynyl group Chemical group 0.000 claims description 8
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 claims description 8
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 7
- 125000004423 acyloxy group Chemical group 0.000 claims description 7
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 150000001266 acyl halides Chemical class 0.000 claims description 6
- 150000008064 anhydrides Chemical class 0.000 claims description 6
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 6
- 239000012948 isocyanate Substances 0.000 claims description 6
- 150000002513 isocyanates Chemical class 0.000 claims description 6
- 150000002540 isothiocyanates Chemical class 0.000 claims description 6
- 125000003544 oxime group Chemical group 0.000 claims description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 5
- 108010061312 Sphingomyelin Phosphodiesterase Proteins 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 102000010126 acid sphingomyelin phosphodiesterase activity proteins Human genes 0.000 claims description 5
- 229960000485 methotrexate Drugs 0.000 claims description 5
- 102000004627 Iduronidase Human genes 0.000 claims description 4
- 108010003381 Iduronidase Proteins 0.000 claims description 4
- 150000001350 alkyl halides Chemical class 0.000 claims description 4
- UWROMLKEISLXAJ-UHFFFAOYSA-N (aminooxyamino)thiourea Chemical compound NONNC(N)=S UWROMLKEISLXAJ-UHFFFAOYSA-N 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000002128 sulfonyl halide group Chemical group 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- 150000001540 azides Chemical class 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- 235000018102 proteins Nutrition 0.000 description 39
- NBSCHQHZLSJFNQ-QTVWNMPRSA-N D-Mannose-6-phosphate Chemical group OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@@H]1O NBSCHQHZLSJFNQ-QTVWNMPRSA-N 0.000 description 33
- 238000006243 chemical reaction Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 150000002772 monosaccharides Chemical class 0.000 description 11
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 102000004157 Hydrolases Human genes 0.000 description 8
- 108090000604 Hydrolases Proteins 0.000 description 8
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 201000004502 glycogen storage disease II Diseases 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 208000024720 Fabry Disease Diseases 0.000 description 6
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 6
- 102000016679 alpha-Glucosidases Human genes 0.000 description 6
- 230000021615 conjugation Effects 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 238000000502 dialysis Methods 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 210000003712 lysosome Anatomy 0.000 description 6
- 230000001868 lysosomic effect Effects 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 6
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 5
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 5
- 230000005856 abnormality Effects 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 125000005842 heteroatom Chemical group 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 150000003384 small molecules Chemical class 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 229910001868 water Inorganic materials 0.000 description 5
- PECYZEOJVXMISF-UHFFFAOYSA-N 3-aminoalanine Chemical compound [NH3+]CC(N)C([O-])=O PECYZEOJVXMISF-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 4
- 229930105110 Cyclosporin A Natural products 0.000 description 4
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 4
- 108010036949 Cyclosporine Proteins 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- 125000003368 amide group Chemical group 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 4
- 229960002170 azathioprine Drugs 0.000 description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 238000010647 peptide synthesis reaction Methods 0.000 description 4
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 4
- HJBLUNHMOKFZQX-UHFFFAOYSA-N 3-hydroxy-1,2,3-benzotriazin-4-one Chemical compound C1=CC=C2C(=O)N(O)N=NC2=C1 HJBLUNHMOKFZQX-UHFFFAOYSA-N 0.000 description 3
- PZUPAGRIHCRVKN-UHFFFAOYSA-N 5-[5-[3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]-5-[3,4,5-trihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxyoxan-2-yl]oxy-3,4-dihydroxy-6-[(3,4,5-trihydroxyoxan-2-yl)oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound OCC1OC(O)C(O)C(O)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(COC4C(C(O)C(O)CO4)O)O3)O)C(COC3C(C(O)C(O)CO3)O)O2)O)C(COC2C(C(O)C(O)CO2)O)O1 PZUPAGRIHCRVKN-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920002527 Glycogen Polymers 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 150000001263 acyl chlorides Chemical class 0.000 description 3
- 150000001265 acyl fluorides Chemical class 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 239000007822 coupling agent Substances 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229940096919 glycogen Drugs 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 210000001626 skin fibroblast Anatomy 0.000 description 3
- 239000007974 sodium acetate buffer Substances 0.000 description 3
- 150000003461 sulfonyl halides Chemical class 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- NBNBICNWNFQDDD-UHFFFAOYSA-N sulfuryl dibromide Chemical compound BrS(Br)(=O)=O NBNBICNWNFQDDD-UHFFFAOYSA-N 0.000 description 3
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 150000004044 tetrasaccharides Chemical class 0.000 description 3
- 231100001274 therapeutic index Toxicity 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 150000004043 trisaccharides Chemical class 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 2
- GMKMEZVLHJARHF-UHFFFAOYSA-N 2,6-diaminopimelic acid Chemical compound OC(=O)C(N)CCCC(N)C(O)=O GMKMEZVLHJARHF-UHFFFAOYSA-N 0.000 description 2
- QBXODCKYUZNZCY-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]oxyacetic acid Chemical compound CC(C)(C)OC(=O)NOCC(O)=O QBXODCKYUZNZCY-UHFFFAOYSA-N 0.000 description 2
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- JUQLUIFNNFIIKC-UHFFFAOYSA-N 2-aminopimelic acid Chemical compound OC(=O)C(N)CCCCC(O)=O JUQLUIFNNFIIKC-UHFFFAOYSA-N 0.000 description 2
- YUDPTGPSBJVHCN-JZYAIQKZSA-N 4-Methylumbelliferyl-alpha-D-glucopyranoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-JZYAIQKZSA-N 0.000 description 2
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- 208000006029 Cardiomegaly Diseases 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 2
- 101000702579 Crotalus durissus terrificus Snaclec crotocetin Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010015133 Galactose oxidase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101001018026 Homo sapiens Lysosomal alpha-glucosidase Proteins 0.000 description 2
- 206010023509 Kyphosis Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010056886 Mucopolysaccharidosis I Diseases 0.000 description 2
- 208000010428 Muscle Weakness Diseases 0.000 description 2
- 206010028372 Muscular weakness Diseases 0.000 description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 206010057040 Temperature intolerance Diseases 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000008351 acetate buffer Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 239000012148 binding buffer Substances 0.000 description 2
- 238000004166 bioassay Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 125000004093 cyano group Chemical group *C#N 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- PYLIXCKOHOHGKQ-UHFFFAOYSA-L disodium;hydrogen phosphate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].OP([O-])([O-])=O PYLIXCKOHOHGKQ-UHFFFAOYSA-L 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- 238000002641 enzyme replacement therapy Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000005227 gel permeation chromatography Methods 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 206010019847 hepatosplenomegaly Diseases 0.000 description 2
- ZTVZLYBCZNMWCF-UHFFFAOYSA-N homocystine Chemical compound [O-]C(=O)C([NH3+])CCSSCCC([NH3+])C([O-])=O ZTVZLYBCZNMWCF-UHFFFAOYSA-N 0.000 description 2
- 102000045921 human GAA Human genes 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 238000000099 in vitro assay Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- RTGDFNSFWBGLEC-SYZQJQIISA-N mycophenolate mofetil Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 description 2
- 229960004866 mycophenolate mofetil Drugs 0.000 description 2
- 150000002812 neutral glycosphingolipids Chemical class 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 229960005489 paracetamol Drugs 0.000 description 2
- 208000035824 paresthesia Diseases 0.000 description 2
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 201000001474 proteinuria Diseases 0.000 description 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 2
- 201000004193 respiratory failure Diseases 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 206010039722 scoliosis Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 229960002930 sirolimus Drugs 0.000 description 2
- 201000002859 sleep apnea Diseases 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
- DPKBAXPHAYBPRL-UHFFFAOYSA-M tetrabutylazanium;iodide Chemical compound [I-].CCCC[N+](CCCC)(CCCC)CCCC DPKBAXPHAYBPRL-UHFFFAOYSA-M 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- RCIVUMDLBQZEHP-UHFFFAOYSA-N (2-methylpropan-2-yl)oxycarbamic acid Chemical compound CC(C)(C)ONC(O)=O RCIVUMDLBQZEHP-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- FDKWRPBBCBCIGA-REOHCLBHSA-N (2r)-2-azaniumyl-3-$l^{1}-selanylpropanoate Chemical compound [Se]C[C@H](N)C(O)=O FDKWRPBBCBCIGA-REOHCLBHSA-N 0.000 description 1
- UCKLRJLHKVCNAU-LURJTMIESA-N (2s)-2-(1,3-benzothiazol-2-ylamino)propanoic acid Chemical compound C1=CC=C2SC(N[C@@H](C)C(O)=O)=NC2=C1 UCKLRJLHKVCNAU-LURJTMIESA-N 0.000 description 1
- BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
- XQBUAEBDRUXSPI-ZETCQYMHSA-N (2s)-2-(piperidin-1-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NN1CCCCC1 XQBUAEBDRUXSPI-ZETCQYMHSA-N 0.000 description 1
- WTYDPHLGAWMABS-LURJTMIESA-N (2s)-2-(pyrrolidin-1-ylamino)propanoic acid Chemical compound OC(=O)[C@H](C)NN1CCCC1 WTYDPHLGAWMABS-LURJTMIESA-N 0.000 description 1
- SJTPYAOZAPSOLO-REOHCLBHSA-N (2s)-2-hydrazinyl-3-hydroxypropanoic acid Chemical compound NN[C@@H](CO)C(O)=O SJTPYAOZAPSOLO-REOHCLBHSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- MVBGEDKDDSYSNF-STQMWFEESA-N (3s,4s)-4-(cyclohexylamino)-3-hydroxy-6-methylheptanoic acid Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC1CCCCC1 MVBGEDKDDSYSNF-STQMWFEESA-N 0.000 description 1
- LDXFNKACRSEQND-ULUSZKPHSA-N (5R)-1-azabicyclo[3.1.0]hexane-5-carboxylic acid Chemical compound C1CC[C@@]2(C(=O)O)N1C2 LDXFNKACRSEQND-ULUSZKPHSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- IADUEWIQBXOCDZ-VKHMYHEASA-N (S)-azetidine-2-carboxylic acid Chemical compound OC(=O)[C@@H]1CCN1 IADUEWIQBXOCDZ-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- NILQLFBWTXNUOE-UHFFFAOYSA-N 1-aminocyclopentanecarboxylic acid Chemical compound OC(=O)C1(N)CCCC1 NILQLFBWTXNUOE-UHFFFAOYSA-N 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- RJAIAYPCDGYRLY-UHFFFAOYSA-N 2,2,2-trichloroethylcarbamic acid Chemical compound OC(=O)NCC(Cl)(Cl)Cl RJAIAYPCDGYRLY-UHFFFAOYSA-N 0.000 description 1
- NRKYWOKHZRQRJR-UHFFFAOYSA-N 2,2,2-trifluoroacetamide Chemical group NC(=O)C(F)(F)F NRKYWOKHZRQRJR-UHFFFAOYSA-N 0.000 description 1
- SJROICLOHTWSGE-UHFFFAOYSA-N 2,3-dimethyl-1,3-thiazolidine-2-carboxylic acid Chemical compound CN1CCSC1(C)C(O)=O SJROICLOHTWSGE-UHFFFAOYSA-N 0.000 description 1
- GVJXGCIPWAVXJP-UHFFFAOYSA-N 2,5-dioxo-1-oxoniopyrrolidine-3-sulfonate Chemical compound ON1C(=O)CC(S(O)(=O)=O)C1=O GVJXGCIPWAVXJP-UHFFFAOYSA-N 0.000 description 1
- RRWZZMHRVSMLCT-UHFFFAOYSA-N 2-(butylazaniumyl)acetate Chemical compound CCCCNCC(O)=O RRWZZMHRVSMLCT-UHFFFAOYSA-N 0.000 description 1
- PRSWALMQXKFZFA-UHFFFAOYSA-N 2-(piperidin-1-ylamino)acetic acid Chemical compound OC(=O)CNN1CCCCC1 PRSWALMQXKFZFA-UHFFFAOYSA-N 0.000 description 1
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 1
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- JUAGNSFMKLTCCT-UHFFFAOYSA-N 2-aminoacetic acid;carbonic acid Chemical compound OC(O)=O.NCC(O)=O JUAGNSFMKLTCCT-UHFFFAOYSA-N 0.000 description 1
- ICBKJQDJWHBQAX-UHFFFAOYSA-N 2-aminooxane-4-carboxylic acid Chemical compound NC1CC(C(O)=O)CCO1 ICBKJQDJWHBQAX-UHFFFAOYSA-N 0.000 description 1
- VRFJLUHAQPBTLE-UHFFFAOYSA-N 2-aminopiperidine-1-carboxylic acid Chemical compound NC1CCCCN1C(O)=O VRFJLUHAQPBTLE-UHFFFAOYSA-N 0.000 description 1
- WTOFYLAWDLQMBZ-UHFFFAOYSA-N 2-azaniumyl-3-thiophen-2-ylpropanoate Chemical compound OC(=O)C(N)CC1=CC=CS1 WTOFYLAWDLQMBZ-UHFFFAOYSA-N 0.000 description 1
- YHFKJGZDKILHTL-UHFFFAOYSA-N 3-(aminomethyl)-1h-pyrrole-2-carboxylic acid Chemical compound NCC=1C=CNC=1C(O)=O YHFKJGZDKILHTL-UHFFFAOYSA-N 0.000 description 1
- NUBOMXHHTQFVBI-UHFFFAOYSA-N 4-[2-amino-5-[4-amino-3-(3-carboxypropoxy)phenyl]phenoxy]butanoic acid Chemical compound C1=C(OCCCC(O)=O)C(N)=CC=C1C1=CC=C(N)C(OCCCC(O)=O)=C1 NUBOMXHHTQFVBI-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- PCNFLKVWBDNNOW-UHFFFAOYSA-N 4-hydrazinylbenzoic acid Chemical compound NNC1=CC=C(C(O)=O)C=C1 PCNFLKVWBDNNOW-UHFFFAOYSA-N 0.000 description 1
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 description 1
- NUNAFZBLRYLEDP-UHFFFAOYSA-N 9h-fluoren-9-ylmethylcarbamic acid Chemical compound C1=CC=C2C(CNC(=O)O)C3=CC=CC=C3C2=C1 NUNAFZBLRYLEDP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000034012 Acid sphingomyelinase deficiency Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002915 Aortic valve incompetence Diseases 0.000 description 1
- 241001550224 Apha Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 102000005427 Asialoglycoprotein Receptor Human genes 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 0 C*C[C@]([C@](C([C@](C)O)O)O)OOC(C1O)[C@@](OCC([C@](C(C2O)O)O)O[C@@]2OCC([C@](C(C2O)O[C@](C(C3O)O[C@](C4O)O[C@](C*)[C@@](*)C4O)O[C@](CO)[C@@]3O)O)O[C@]2O*C*(C)C(NNC(*(C)C*ON)=O)=O)OC(CO)[C@]1O Chemical compound C*C[C@]([C@](C([C@](C)O)O)O)OOC(C1O)[C@@](OCC([C@](C(C2O)O)O)O[C@@]2OCC([C@](C(C2O)O[C@](C(C3O)O[C@](C4O)O[C@](C*)[C@@](*)C4O)O[C@](CO)[C@@]3O)O)O[C@]2O*C*(C)C(NNC(*(C)C*ON)=O)=O)OC(CO)[C@]1O 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 1
- 101710145225 Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 1
- 208000000781 Conductive Hearing Loss Diseases 0.000 description 1
- 206010010280 Conductive deafness Diseases 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000006069 Corneal Opacity Diseases 0.000 description 1
- FDKWRPBBCBCIGA-UWTATZPHSA-N D-Selenocysteine Natural products [Se]C[C@@H](N)C(O)=O FDKWRPBBCBCIGA-UWTATZPHSA-N 0.000 description 1
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 206010012559 Developmental delay Diseases 0.000 description 1
- 208000003164 Diplopia Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013971 Dyspnoea exertional Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- NIGWMJHCCYYCSF-UHFFFAOYSA-N Fenclonine Chemical compound OC(=O)C(N)CC1=CC=C(Cl)C=C1 NIGWMJHCCYYCSF-UHFFFAOYSA-N 0.000 description 1
- 208000005622 Gait Ataxia Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000008017 Hypohidrosis Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 208000029836 Inguinal Hernia Diseases 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- QUOGESRFPZDMMT-UHFFFAOYSA-N L-Homoarginine Natural products OC(=O)C(N)CCCCNC(N)=N QUOGESRFPZDMMT-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-UHNVWZDZSA-N L-allo-Isoleucine Chemical compound CC[C@@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-UHNVWZDZSA-N 0.000 description 1
- ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- QUOGESRFPZDMMT-YFKPBYRVSA-N L-homoarginine Chemical compound OC(=O)[C@@H](N)CCCCNC(N)=N QUOGESRFPZDMMT-YFKPBYRVSA-N 0.000 description 1
- XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 206010024214 Lenticular opacities Diseases 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 206010024602 Lipiduria Diseases 0.000 description 1
- 208000007623 Lordosis Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100025354 Macrophage mannose receptor 1 Human genes 0.000 description 1
- 108010031099 Mannose Receptor Proteins 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 208000020128 Mitral stenosis Diseases 0.000 description 1
- 206010027727 Mitral valve incompetence Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 230000004989 O-glycosylation Effects 0.000 description 1
- 206010030348 Open-Angle Glaucoma Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010041549 Spinal cord compression Diseases 0.000 description 1
- 239000012317 TBTU Substances 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N Tetraethylene glycol, Natural products OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 206010048215 Xanthomatosis Diseases 0.000 description 1
- 241000212749 Zesius chrysomallus Species 0.000 description 1
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical group OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 150000001371 alpha-amino acids Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- 150000001408 amides Chemical group 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 201000009431 angiokeratoma Diseases 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 206010002906 aortic stenosis Diseases 0.000 description 1
- 201000002064 aortic valve insufficiency Diseases 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000009697 arginine Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 108010006523 asialoglycoprotein receptor Proteins 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 150000001576 beta-amino acids Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical group 0.000 description 1
- 210000005242 cardiac chamber Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 102000028740 cation-dependent mannose-6-phosphate receptor Human genes 0.000 description 1
- 108010090156 cation-dependent mannose-6-phosphate receptor Proteins 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 201000009151 chronic rhinitis Diseases 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 208000023563 conductive hearing loss disease Diseases 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000008094 contradictory effect Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 230000009144 enzymatic modification Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
- 206010016165 failure to thrive Diseases 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 239000012537 formulation buffer Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 206010019465 hemiparesis Diseases 0.000 description 1
- 239000008241 heterogeneous mixture Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002962 histologic effect Effects 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- SRJOCJYGOFTFLH-UHFFFAOYSA-N isonipecotic acid Chemical compound OC(=O)C1CCNCC1 SRJOCJYGOFTFLH-UHFFFAOYSA-N 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- UQRORFVVSGFNRO-UTINFBMNSA-N miglustat Chemical compound CCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO UQRORFVVSGFNRO-UTINFBMNSA-N 0.000 description 1
- 229960001512 miglustat Drugs 0.000 description 1
- 208000006887 mitral valve stenosis Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000001964 muscle biopsy Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- ZUSSTQCWRDLYJA-UHFFFAOYSA-N n-hydroxy-5-norbornene-2,3-dicarboximide Chemical compound C1=CC2CC1C1C2C(=O)N(O)C1=O ZUSSTQCWRDLYJA-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 206010029864 nystagmus Diseases 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- OCAAZRFBJBEVPS-UHFFFAOYSA-N prop-2-enyl carbamate Chemical compound NC(=O)OCC=C OCAAZRFBJBEVPS-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 235000016491 selenocysteine Nutrition 0.000 description 1
- 229940055619 selenocysteine Drugs 0.000 description 1
- ZKZBPNGNEQAJSX-UHFFFAOYSA-N selenocysteine Natural products [SeH]CC(N)C(O)=O ZKZBPNGNEQAJSX-UHFFFAOYSA-N 0.000 description 1
- 231100000879 sensorineural hearing loss Toxicity 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 229960001153 serine Drugs 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- DFVFTMTWCUHJBL-BQBZGAKWSA-N statine Chemical compound CC(C)C[C@H](N)[C@@H](O)CC(O)=O DFVFTMTWCUHJBL-BQBZGAKWSA-N 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 206010045458 umbilical hernia Diseases 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/738—Cross-linked polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/02—Acyclic radicals, not substituted by cyclic structures
- C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01022—Alpha-galactosidase (3.2.1.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
Definitions
- the invention relates generally to methods for the synthesis of oligosaccharides comprising an aminooxy group from oligosaccharides comprising a reactive group.
- the invention further relates to oligosaccharides comprising an aminooxy group.
- the invention also relates to methods of conjugating oligosaccharides comprising an aminooxy group to proteins, including glycoproteins (such as, e.g., lysosomal enzymes), and to compositions of oligosaccharide-protein conjugates, including oligosaccharide- glycoprotein conjugates.
- Another embodiment of the invention relates to methods of treating lysosomal storage disorders using such oligosaccharide-lysosomal enzyme conjugates.
- LSDs Lysosomal storage disorders
- a hallmark feature of LSDs is the abnormal accumulation of lysosomal metabolites, which leads to the formation of large numbers of distended lysosomes.
- LSDs can be treated by administration of the active version of the enzyme deficient in the patient, a process termed enzyme replacement therapy (ERT).
- ERT enzyme replacement therapy
- the administered replacement enzyme bearing a terminal mannose-6- phosphate (M6P) is taken up by target cells through cell-surface-associated cation-independent M6P receptor (CI-MPR)-mediated endocytosis, and directed to the lysosome.
- M6P mannose-6- phosphate
- CI-MPR cell-surface-associated cation-independent M6P receptor
- U.S. Patent No. 7,001 ,994 describes a method for coupling oligosaccharides comprising M6P with glycoproteins.
- the oligosaccharides of the glycoproteins are first oxidized with periodate or galactose oxidase to result in the formation of carbonyl groups, which are then chemically conjugated with an oligosaccharide functionalized at the reducing end with a carbonyl-reactive group (such as, e.g., a hydrazine, hydrazide, aminooxy, thiosemicarbazide, semicarbazide, or amine group) to yield an oligosaccharide-glycoprotein conjugate.
- a carbonyl-reactive group such as, e.g., a hydrazine, hydrazide, aminooxy, thiosemicarbazide, semicarbazide, or amine group
- a conjugate of the lysosomal enzyme acid ⁇ -glucosidase (GAA) with a a bis-M6P oligosaccharide was prepared by the above-described method, and found to be more effective in reducing skeletal and cardiac muscle glycogen than recombinant human GAA in a murine model of Pompe disease, an autosomal recessive muscular disease resulting from a metabolic deficiency of GAA, and characterized by the accumulation of lysosomal glycogen.
- Aminooxy groups are particularly useful carbonyl-reactive groups for the conjugation reactions described above, as the resulting conjugates comprise a relatively stable oxime linkage. Therefore, there is a need for methods for the preparation of aminooxy functionalized oligosaccharides.
- the present invention provides methods of preparing oligosaccharides comprising an aminooxy group. These methods are generally applicable to a broad range of protected and unprotected oligosaccharides, such as, e.g., branched and unbranched, and phosphorylated and unphosphorylated, oligosaccharides.
- the oligosaccharide may be a disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, hexasaccharide, heptasaccharide, or greater.
- the oligosaccharide may, in certain embodiments, comprise at least one M6P residue. In some embodiments, the oligosaccharide may comprise at least 1 , 2, 3, 4, 5, 6, or 7 terminal M6P residues.
- the invention provides a method of preparing an oligosaccharide comprising an aminooxy group from an oligosaccharide comprising a reactive group.
- the method comprises:
- the first and second reactive groups may be chosen from, e.g., hydrazine, hydrazide, thiosemicarbazide, semicarbazide, amine, carboxyl, activated ester, acyl halide, acyl azide, alkyl halide, anhydride, isothiocyanate, isocyanate, and sulfonyl halide groups.
- aminooxy compound is chosen from compounds of Formula II:
- Y is the second reactive group
- Z is chosen from alkyl, alkenyl, alkynyl, aryl, heteroaryl, and heterocyclyl
- P is chosen from amino protecting groups (such as, e.g., carbamate protecting groups).
- Y may be a carboxyl, activated ester, acyl halide (such as, e.g., an acyl fluoride or acyl chloride), acyl azide, alkyl halide, anhydride, isothiocyanate, isocyanate, or sulfonyl halide (such as, e.g., a sulfonyl chloride or sulfonyl bromide).
- Y may be, e.g., a hydrazine, hydrazide, thiosemicarbazide, semicarbazide, or amine group.
- the aminooxy compound of Formula Il is chosen from compounds of Formula III: n ⁇ Y P
- Y is the second reactive group
- n is chosen from integers ranging from 1 to 10
- P is chosen from amino protecting groups.
- the aminooxy compound comprises an amino protecting group
- the method further comprises a step (d), deprotecting the oligosaccharide comprising an aminooxy group.
- the invention further provides an oligosaccharide comprising (1 ) an aminooxy group and (2) mannose-6-phosphate.
- that oligosaccharide is prepared by the methods described above.
- the invention provides an oligosaccharide comprising an aminooxy group of Formula IV:
- the invention provides an oligosaccharide of Formula V:
- the invention provides methods of coupling an oligosaccharide to a protein.
- the method comprises:
- the invention further provides an oligosaccharide-protein conjugate comprising (1 ) a protein, (2) an oligosaccharide, and (3) an oxime group connecting the protein and the oligosaccharide.
- the invention provides an oligosaccharide-protein conjugate prepared by the methods disclosed above.
- the oligosaccharide-protein conjugate is an oligosaccharide-glycoprotein conjugate.
- the oligosaccharide-glycoprotein conjugate is the conjugate of an oligosaccharide comprising at least one M6P and of a lysosomal enzyme such as, e.g., a lysosomal hydrolase.
- the invention provides pharmaceutical compositions comprising an oligosaccharide- protein conjugate of the invention.
- Another embodiment of the invention provides methods of treating a lysosomal storage disorder such as, e.g., those disclosed in Table 1.
- the methods comprise administering to a mammal an oligosaccharide-glycoprotein conjugate of the invention, wherein the oligosaccharide comprises at least one M6P and the glycoprotein is a lysosomal hydrolase.
- This disclosure further provides the use of a conjugate of the invention for treating a lysosomal storage disorder in a subject in need thereof, and in the manufacture of a medicament for treating a lysosomal storage disorder.
- FIG. 1 is a reaction scheme depicting an illustrative embodiment of the methods of the invention.
- Oligosaccharide 1 having a first reactive group (a hydrazide group), is reacted with aminooxy compound 2 in presence of the catalyst 3-hydroxy-1 ,2,3-benzotriazin-4(3H)-one (DHBt-OH), to yield oligosaccharide 3.
- the tert-butyloxycarbonyl (t-Boc) amino protecting group of oligosaccharide 3 is then removed with 50% trifluoroacetic acid / dichloromethane (TFA/DCM) to yield oligosaccharide 4.
- TFA/DCM trifluoroacetic acid / dichloromethane
- Figure 2 depicts a series of gel chromatographs of intermediates in the synthetic scheme described in Figure 1.
- Figure 2A is a Dionex analytical chromatograph of starting oligosaccharide 1.
- Figure 2B is a Dionex analytical chromatograph of oligosaccharide 3.
- Figure 2C is a Dionex analytical chromatograph of oligosaccharide 4.
- FIG. 4 is a reaction scheme depicting an illustrative embodiment of the methods of the invention.
- Oligosaccharide 5 having a first reactive group (a carboxyl group) is reacted with aminooxy compound 6 in presence of the coupling agent 1 -ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and the catalyst N-hydroxysuccinimide (NHS) 1 to yield aminooxy-containing oligosaccharide 3.
- EDC ethyl-3-(3-dimethylaminopropyl)-carbodiimide
- NHS N-hydroxysuccinimide
- an oligosaccharide refers to a disaccharide, trisaccharide, tetrasaccharide, pentasaccharide, hexasaccharide, heptasaccharide, or larger oligosaccharide (such as, e.g., an oligosaccharide comprising 2-50, 2-10, 8-25, or 8-50 saccharide units).
- an oligosaccharide may be, e.g., a disaccharide, trisaccharide, tetrasaccharide, a pentasaccharide, a hexasaccharide, a heptasaccharide, or a larger oligosaccharide.
- An oligosaccharide may be mono-, bi-, tri-, tetra-, or penta-antennary in structure.
- An oligosaccharide may comprise 0, 1 , 2, 3, 4, or more branch points.
- the reactive group on the oligosaccharide also referred to as a first reactive group, may be, in some embodiments, e.g., a hydrazine group, hydrazide group, semicarbazide group, thiosemicarbazide, or amine group.
- the first reactive group may be, e.g., a carboxyl, ester (such as, e.g., an activated ester), acyl halide (such as, e.g., acyl fluoride or acyl chloride), acyl azide, alkyl halide, anhydride, isothiocyanate, isocyanate, or sulfonyl halide (such as, e.g., sulfonyl chloride or sulfonyl bromide) group.
- the first reactive group may be connected to the reducing end of the oligosaccharide or may be located anywhere in the oligosaccharide.
- the first reactive group may, in certain embodiments, be connected through one or more linkers to the oligosaccharide.
- a linker as used herein, may be chosen from, e.g., a combination of optionally substituted alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, acyloxy, alkoxy, aryloxy, and heterocyclyloxy groups.
- a linker may be interrupted or terminated by one or more heteroatoms such as, e.g., nitrogen, sulfur, and oxygen.
- a linker in some embodiments, may comprise one or more ether, ester, or amide group.
- linker any chemical group of the linker (such as, e.g., alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, acyloxy, alkoxy, aryloxy, and heterocyclyloxy) may be substituted or unsubstituted, unless otherwise stated.
- linker such as, e.g., alkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclyl, acyloxy, alkoxy, aryloxy, and heterocyclyloxy
- Substituents may be chosen from, e.g., acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, azido, carbamoyl, carboalkoxy, carboxy, cyano, cycloalkyl, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonate, sulfonyl, thio, thioacylamino, thioureido, and ureido.
- the substituents may themselves be substituted or unsubstituted, and may be interrupted or terminated by one or more heteroatoms such as, e.g., nitrogen, sulfur, and oxygen.
- an oligosaccharide may comprise at least one protecting group.
- protecting group refers to any substituent that may be used to prevent a functional group (such as, e.g., an amine group, a carboxyl group, a hydroxyl group, a hydrazine group, a hydrazide group, a semicarbazide group, or a thiosemicarbazide group) on a molecule from undergoing a chemical reaction while chemical change occurs elsewhere in the molecule.
- a protecting group can be removed under the appropriate chemical conditions.
- the oligosaccharide may comprise at least one protecting group chosen from hydroxyl protecting groups, carboxyl protecting groups, and amino protecting groups. In other embodiments, an oligosaccharide may be "unprotected," and may not comprise any protecting groups.
- An oligosaccharide may be isolated from a natural source or may be prepared by chemical or enzymatic synthesis.
- An oligosaccharide isolated from a natural source may be homogeneous or may be a heterogeneous mixture of related oligosaccharides.
- an oligosaccharide may be prepared by chemical or enzymatic modification of an oligosaccharide isolated from a natural source ("semi-synthesis").
- the oligosaccharide may be a synthetic oligosaccharide having the chemical structure of a naturally occurring oligosaccharide.
- an oligosaccharide may comprise a monosaccharide that is recognized by a particular receptor.
- the monosaccharide recognized by a particular receptor may be chosen from, e.g., galactose, GaINAc, mannose, M6P, glucose, GIcNAc, sialic acid, or sulfated sialic acid residue.
- An oligosaccharide may, in certain embodiments, comprise at least one M6P residue, such as, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 M6P residues.
- the monosaccharide recognized by a particular receptor may be, in some embodiments, a penultimate monosaccharide or a terminal monosaccharide.
- the monosaccharide recognized by a particular receptor may be a terminal galactose, mannose, M6P, glucose, GIcNAc, or sialic acid residue.
- An oligosaccharide may, in some embodiments, contain at least 1 , 2, 3, 4, 5, 6, 7 terminal M6P residues.
- the oligosaccharide comprising a reactive group may be an M6P-containing hexasaccharide of Formula Ia:
- the oligosaccharide of Formula Ia can be described as butyrylhydrazine-4-yl 6-O-phosphono- ⁇ -D-mannopyranosyl-(1 ⁇ 2)- ⁇ -D- mannopyranosyl-(1 ⁇ 6)- ⁇ -D-mannopyranosyl-(1 ⁇ 6)-[6-O-phosphono- ⁇ -D- mannopyranosyl-(1 ⁇ 2)- ⁇ -D-mannopyranosyl-(1 ⁇ 3)]- ⁇ -D-mannopyranoside.
- the oligosaccharide comprising a reactive group may be an M6P-containing hexasaccharide of Formula Ib:
- an aminooxy compound may be any compound comprising an aminooxy group and a second reactive group, wherein the second reactive group may react with a first reactive group on an oligosaccharide to form a covalent bond.
- the second reactive group may be a carboxyl, ester (such as, e.g., an activated ester), acyl halide (such as, e.g., an acyl fluoride or acyl chloride), acyl azide, anhydride, isothiocyanate, isocyanate, or sulfonyl halide (such as, e.g., a sulfonyl chloride or sulfonyl bromide) group.
- the second reactive group may be, e.g., a hydrazine group, hydrazide group, semicarbazide group, thiosemicarbazide, or amine group.
- the nitrogen of the aminooxy group of the aminooxy compound is protected with an amino protecting group.
- amino protecting groups are known to those skilled in the art, and examples of amino protecting groups, methods for their addition, and methods for their removal can be found in pp.
- aminooxy compound is chosen from compounds of Formula II:
- Y is the second reactive group
- Z is chosen from alkyl, alkenyl, alkynyl, heteroaryl, aryl, and heterocyclyl
- P is chosen from amino protecting groups.
- any chemical group on the aminooxy compound may be substituted or unsubstituted, and may be interrupted by one or more chemical groups, unless otherwise stated.
- Substituents and interrupting chemical groups may be chosen from, e.g., acyl, acylamino, acyloxy, alkenyl, alkoxy, alkyl, alkynyl, amido, amino, aryl, aryloxy, azido, carbamoyl, carboalkoxy, carboxy, cyano, cycloalkyl, formyl, guanidino, halo, heteroaryl, heterocyclyl, hydroxy, iminoamino, nitro, oxo, phosphonamino, sulfinyl, sulfonamino, sulfonate, sulfonyl, thio, thioacylamino, thioureido, and ureido.
- the substituents may themselves be substituted or unsubstituted, and may be interrupted or terminated by one or more heteroatoms such as, e.g., nitrogen, sulfur, and oxygen
- Y may be chosen from, for example: wherein X is chosen from halogens, azide, acyloxy, alkoxy, aryloxy, heteroaryloxy, and heterocyclyloxy.
- the aminooxy compound is an activated ester.
- an activated ester is an ester that reacts to form an amide bond under mild conditions.
- an activated ester is an ester of a relatively acidic alcohol.
- Formula Il is an activated ester of formula , and X is chosen from alkoxy, aryloxy, heteroaryloxy, and heterocyclyloxy.
- X may be chosen from:
- Y is chosen from, e.g., hydrazide, hydrazine, thiosemicarbazide, semicarbazide, and amine groups.
- Z may comprise, for example, a carbonyl, ether, ester, or amide group.
- Z may be, for example, alkyl interrupted by one or more heteroatoms, such as an oligoethyleneglycol.
- Z may be monoethyleneglycol, diethyleneglycol, triethyleneglycol, tetraethyleneglycol, or larger oligoethyleneglycol.
- Z may be, for example, alkyl substituted with oxo and interrupted by one or more heteroatoms, such as an oligopeptide.
- the oligopeptide may comprise one, two, three, four, five, six, or more component amino acids.
- the amino acids may be, for example, ⁇ -amino acids, ⁇ -amino acids, ⁇ -amino acids, ⁇ -amino acids, and ⁇ -amino acids.
- An amino acid may have R or S chirality at any chiral atom.
- amino acid may be chosen from, e.g., alanine, ⁇ -alanine, ⁇ -aminoadipic acid, 2-aminobutanoic acid, 4-aminobutanoic acid, 1 -aminocyclopentanecarboxylic acid, 6-aminohexanoic acid, 2-aminoheptanedioic acid, 7-aminoheptanoic acid, 2-aminoisobutyric acid, aminomethylpyrrole carboxylic acid, 8-amino-3,6-dioxa-octanoic acid, aminopiperidinecarboxylic acid, 3-amino-propionic acid, aminoserine, aminotetrahydropyran-4-carboxylic acid, arginine, asparagine, aspartic acid, azetidine carboxylic acid, benzothiazolylalanine, butylglycine, carnitine, 4-chlorophenylalanine, citrulline,
- P may be chosen from amino protecting groups known to those of skill in the art.
- P may be a carbamate protecting group, such as, e.g., a (9-fluorenylmethyl)carbamate (Fmoc), (tert-butyloxy)carbamate (t- Boc), (trichloroethyl)carbamate (Troc), or allylcarbamate (Alloc) protecting group.
- P may be a non-carbamate protecting group, such as, e.g., an amide protecting group such as a phthalimide or a trifluoroacetamide protecting group.
- aminooxy compound of Formula Il is chosen from compounds of Formula III:
- Y and P are as disclosed above, and n is chosen from integers ranging from 1 to 10.
- n may be chosen from integers from the following ranges: 1-4, 2-6, 2-8, 3-6, and 4-10. In illustrative embodiments, n is 1.
- the aminooxy compound is t-Boc- aminooxy acetic acid tetrafluorophenyl ester, the structure of which is depicted below.
- the aminooxy compound has the structure depicted below.
- the invention provides a method of preparing an oligosaccharide comprising an aminooxy group from an oligosaccharide comprising a reactive group.
- the method comprises:
- the oligosaccharide comprising a first reactive compound may be, e.g., any oligosaccharide comprising a reactive group as described supra.
- the oligosaccharide comprising a first reactive group is an oligosaccharide of Formula Ia or an oligosaccharide of Formula Ib.
- the aminooxy compound comprising a second reactive group may be any aminooxy compound comprising a reactive group, as described supra.
- first reactive group and “second reactive group,” as used herein, do not denote any particular experimental sequence.
- step (c) reacting the first reactive group of the oligosaccharide with the second reactive group of the aminooxy compound, may be accomplished by any order of addition of the reactants.
- the oligosaccharide comprising a first reactive group may be added to the aminooxy compound comprising the second reactive group, or vice versa.
- both the oligosaccharide and the aminooxy compound may be added simultaneously to a reaction vessel.
- Step (c) may occur under any suitable conditions (e.g., solvent and temperature) known to those of ordinary skill in the art.
- one or more additional reagents such as, e.g., coupling reagents and catalysts, may be present during step (c).
- a coupling reagent is a reagent that may be used to form a covalent bond between the first reactive group and the second reactive group.
- the reaction conditions may comprise a coupling reagent.
- Coupling reagents may be chosen from, e.g., phosphonium coupling reagents such as, e.g., BOP (benzotriazole-i -yl-oxy-tris-(dimethylamino)- phosphonium hexafluorophosphate), PyBOP® (benzotriazole-1-yl-oxy-tris- pyrrolidino-phosphonium hexafluorophosphate), and PyBroP® (bromo-tris- pyrrolidino-phosphonium hexafluorophosphate), and from aminium (uronium) coupling reagents such as, e.g., HBTU
- Coupling reagents may also be chosen from, e.g., carbodiimide coupling reagents such as, e.g., DIC (1 ,3-diisopropylcarbodiimide), CDI (1 ,1' carbonyl diimidazole), and EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide).
- carbodiimide coupling reagents such as, e.g., DIC (1 ,3-diisopropylcarbodiimide), CDI (1 ,1' carbonyl diimidazole), and EDC (1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide).
- the coupling reagent is EDC.
- the reaction conditions comprise both a coupling reagent and a catalyst.
- the reaction conditions may, in certain embodiments, comprise a catalyst.
- the catalyst may be chosen from any suitable catalyst known to those of skill in the art, such as, e.g., DHBt-OH (3-hydroxy-1 ,2,3-benzotriazin-4(3H)-one), HOBt (N-hydroxybenzotriazole), DMAP (4-dimethylaminopyridine), NHS (N-hydroxysuccinimide), N-hydroxysulfosuccinimide, HONB (N-hydroxy-5- norbornene-endo-2,3-dicarboximide), or a tetrabutylammonium salt such as, e.g., TBAI (tetrabutylammonium iodide).
- the reaction conditions comprise the catalyst DHBt-OH or the catalyst NHS.
- step (c), reacting the first reactive group of the oligosaccharide with the second reactive group of the aminooxy compound results in the formation of an amide bond.
- Conditions suitable for the formation of an amide bond are well known to those of ordinary skill in the art, and are described in, e.g., Chan et al., eds., Fmoc Solid Phase Peptide Synthesis: A Practical Approach, Oxford University Press: New York, 2000; Bodanszky, Principles of Peptide Synthesis, Springer Verlag: New York, 1993; Lloyd-Williams et al., Chemical Approaches to the Synthesis of Peptides and Proteins, CRC Press: Boca Raton, FL, 1997; and the Novabiochem® (San Diego, CA) Catalog.
- the aminooxy compound comprises an amino protecting group
- the method comprises a further step (d), deprotecting the oligosaccharide comprising an aminooxy group to remove the amino protecting group.
- Deprotection may occur under any suitable conditions known to those of skill in the art, such as, e.g., those taught in pp. 494-653 of Greene et al., Protective Groups in Organic Synthesis, 3 rd ed., John Wiley and Sons: New York, 1999 and Kocienski, Protecting Groups, 3 rd ed., Georg Thieme Verlag: Stuttgard, Germany, 2005, the inventions of which are incorporated herein by reference.
- An illustrative embodiment of the method of the invention provides a method of preparing an M6P-containing oligosaccharide comprising an aminooxy group.
- the method comprises:
- n is chosen from integers ranging from 1 to 10
- P is chosen from amino protecting groups
- Y is a second reactive group
- Y in Formula III is , where X is chosen from hydroxy, aryioxy, heteroaryloxy, and heterocyclyloxy.
- X is
- the aminooxy compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the first reactive group of the oligosaccharide may be reacted with the second reactive group of the aminooxy compound in the presence of a coupling agent, such as, e.g., EDC, and/or a catalyst, such as, e.g., DHBt-OH.
- a coupling agent such as, e.g., EDC
- a catalyst such as, e.g., DHBt-OH.
- Another illustrative embodiment of the method of the invention comprises:
- n is chosen from integers ranging from 1 to 10
- P is chosen from amino protecting groups
- Y is a second reactive group
- Y in Formula III is a hydrazine, hydrazide, aminooxy, thiosemicarbazide, semicarbazide, or amine group.
- Y in Formula III is
- the aminooxy compound is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N
- the first reactive group of the oligosaccharide may be reacted with the second reactive group of the aminooxy compound in the presence of a coupling agent, such as, e.g., EDC, and/or a catalyst, such as, e.g., NHS.
- a coupling agent such as, e.g., EDC
- a catalyst such as, e.g., NHS.
- the present invention also provides oligosaccharides comprising an aminooxy group.
- the invention provides oligosaccharides comprising an aminooxy group prepared by the methods disclosed above.
- the oligosaccharide comprising an aminooxy group may comprise, for example, at least 2, 3, 4, 5, 6, or more monosaccharides, including, e.g., at least one galactose, GaINAc, mannose, M6P, glucose, GIcNAc, sialic acid, or sulfated sialic acid residue.
- Such an oligosaccharide may be mono-, bi-, tri-, tetra-, or penta-antennary in structure, and may contain 0, 1 , 2, 3, 4, or more branch points.
- the present invention provides an oligosaccharide comprising (1) an aminooxy group and (2) mannose-6-phosphate.
- the oligosaccharide comprising an aminooxy group may, in some embodiments, comprise, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 M6P residues.
- the oligosaccharide comprising an aminooxy group may comprise at least 1 , 2, 3, 4, or more terminal or penultimate M6P residues.
- the oligosaccharides comprising an aminooxy group are, in certain embodiments, chosen from oligosaccharides of Formula IV:
- m and p are independently chosen from integers ranging from 1 to 10.
- m and p may be independently chosen from integers selected from the following ranges: 1-4, 2-6, 2-8, 3-6, and 4-10.
- m is 3 and p is 1.
- the aminooxy group is directly linked to the reducing end of the oligosaccharide.
- the oligosaccharide comprising an aminooxy group may be an oligosaccharide of Formula V:
- the oligosaccharide to be conjugated with a protein may be chosen from any oligosaccharide comprising a reactive group, as discussed supra, and from any oligosaccharide comprising an aminooxy group, as discussed supra.
- the oligosaccharide to be conjugated may be an oligosaccharide of Formula Ia, Formula Ib, Formula IV or Formula V.
- the conjugation methods described herein are broadly applicable to any pure protein, partially purified protein, or fragment thereof, having at least one carbonyl group (where a carbonyl group is a ketone or an aldehyde), including isolated proteins and recombinantly or synthetically produced proteins.
- the terms "pure,” “purified,” and “isolated” refer to a molecule that is substantially free of its natural environment. For instance, a pure protein is substantially free of cellular material and/or other proteins from the cell or tissue source from which it is derived. The term refers to preparations that are, for example, at least 70% to 80%, 80% to 90%, 90 to 95%; or at least 95%, 96%, 97%, 98%, 99%, or 100% (w/w) pure.
- the protein may be an enzyme that has optimal activity, as measured by an activity assay, at a pH ranging from 1-7, such as, e.g., 1-3, 2-5, 3-6, 4-5, 5-6, or 4-6.
- the enzyme may have a pH optimum at a pH ranging from 4-6.
- the protein may be an enzyme that has an isoelectric point (pi), ranging from 1 to 8, such as, e.g., from 1-3, 2-5, 3-8, 4-5, 5-6, 4-6, 5-8, 6-8, or 7-8.
- the pi of a protein may be may be measured using, e.g., isoelectric focusing gel electrophoresis.
- the protein containing a carbonyl group is obtained by the use of an expression system having an expanded genetic code, as described in, e.g., Wang et al., Proc. Natl. Acad. Sci. USA 100:56-61 (2003).
- the carbonyl group may be located on amino acid side chain, as translated.
- the protein having at least one carbonyl group is a protein having at least one oligosaccharide (i.e., a glycoprotein).
- a glycoprotein having at least one carbonyl group may be obtained by oxidation of that glycoprotein by any means known to those of skill in the art.
- a glycoprotein having at least one carbonyl group may be obtained by oxidation of that glycoprotein with periodate (e.g., sodium periodate) or with galactose oxidase.
- the carbonyl group may be located at a protein glycosylation site.
- the protein having at least one carbonyl group is a glycoprotein, such as a therapeutic glycoprotein.
- a therapeutic glycoprotein may be targeted to the lysosome by conjugation with an oligosaccharide comprising mannose-6-phosphate.
- the glycoprotein may be a lysosomal enzyme, including an ERT enzyme.
- the enzyme may be a lysosomal hydrolase, including those listed in Table 1.
- the lyosomal hydrolase is chosen from, e.g., ⁇ -glucosidase, ⁇ -galactosidase A 1 and acid sphingomyelinase.
- the lyosomal hydrolase is GAA.
- the glycoprotein may be a glycoprotein having at least 1 , 2, 3, 4, 5, or more ⁇ /-linked or O-linked glycosylated amino acid residues.
- the protein may have 1 , 2, 3, 4, 5 or more consensus sites for ⁇ /-linked or O-linked glycosylation, at least one of which is glycosylated.
- the protein may be a ligand for a receptor.
- the protein may be a glycoprotein that binds to a receptor that recognizes a sugar such as, e.g., mannose or mannose-6-phosphate.
- the glycoprotein may bind to, e.g., the asialoglycoprotein receptor, the cation-dependent mannose-6-phosphate receptor, the insulin-like growth factor I I/cation-independent mannose-6-phosphate receptor, or the macrophage mannose receptor.
- the protein is a glycoprotein that, when conjugated to an oligosaccharide comprising mannose-6-phosphate, is internalized more efficiently by a target cell (e.g., via CI-MPR-mediated endocytosis) than is the corresponding unconjugated glycoprotein.
- the conjugated glycoprotein may be internalized more efficiently than the unconjugated glycoprotein by, e.g., at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 50%, 60%, 70%, 80%, or 90% (w/w) in a given time period.
- At least 2, 3, 4, 5, 6, 7, 8, 9, or 10 fold (w/w) as much of the conjugated glycoprotein may be internalized, relative to the unconjugated glycoprotein, in a given time period.
- the referenced time period may be, for example, 10, 30, 45 minutes or 1 , 2, 3, 5, 6, 12, 24, 48, or 72 hours, or more.
- the invention provides methods of coupling an oligosaccharide to a protein, such as, e.g., a glycoprotein.
- the method comprises:
- the methods further comprise adding a reducing agent to the coupled lysosomal enzyme.
- the reducing agent may be any reducing agent known to those of skill in the art, such as, e.g., sodium cyanoborohydride or sodium triacetoxyborohydride (STAB).
- the invention further provides an oligosaccharide-protein conjugate, comprising (1) a protein, (2) an oligosaccharide, and (3) an oxime group connecting the protein and the oligosaccharide.
- the invention provides an oligosaccharide-protein conjugate prepared by the methods disclosed above.
- the oligosaccharide and protein components of the conjugate may be, for example, any oligosaccharide and protein described herein, wherein a conjugate thereof comprises an oxime group, as depicted below.
- the oxime group depicted below is formally derived by reaction of an aminooxy group and an aldehyde group; oxime groups formally derived by reaction of an aminooxy group and a ketone group are also encompassed by this invention.
- the oligosaccharide-protein conjugate is an oligosaccharide-glycoprotein conjugate. In certain embodiments, the oligosaccharide-protein conjugate is the conjugate of an oligosaccharide comprising at least one M6P and of a lysosomal hydrolase. V. Pharmaceutical Compositions
- This disclosure provides the use of a conjugate of the invention in the manufacture of a medicament for treating a lysosomal storage disorder. It also provides pharmaceutical compositions comprising an oligosaccharide-protein conjugate of the invention. In some embodiments, the pharmaceutical compositions of the invention comprise a conjugate of an oligosaccharide comprising at least one M6P and a lysosomal enzyme.
- compositions of the invention may comprise one or more suitable pharmaceutical excipients.
- Standard pharmaceutical formulation techniques and excipients are well known to persons skilled in the art (see, e.g., 2005 Physicians' Desk Reference ® , Thomson Healthcare: Montvale, NJ, 2004; Remington: The Science and Practice of Pharmacy, 20th ed., Gennado et al., Eds. Lippincott Williams & Wilkins: Philadelphia, PA, 2000.
- the compositions may or may not contain preservatives.
- compositions comprising ⁇ -galactosidase A conjugates may comprise one or more excipients such as, e.g., mannitol, sodium phosphate monobasic monohydrate, and/or sodium phosphate dibasic heptahydrate.
- pharmaceutical compositions comprising conjugates of ⁇ - glucosidase may comprise one or more excipients such as, e.g., mannitol, polysorbate 80, sodium phosphate dibasic heptahydrate, and sodium phosphate monobasic monhydrate.
- the pharmaceutical composition may comprise any of the conjugates described herein either as the sole active compound or in combination with another compound, composition, or biological material.
- the pharmaceutical composition may also comprise one or more small molecules useful for the treatment of a LSD and/or a side effect associated with the LSD.
- the composition may comprise miglustat and/or one or more compounds described in, e.g., U.S. Patent Application Publication Nos. 2003/0050299, 2003/0153768; 2005/0222244; 2005/0267094.
- the formulation of pharmaceutical compositions may vary depending on the intended route of administrations and other parameters (see, e.g., Rowe et al.
- the composition may be a sterile, non-pyrogenic, white to off-white lyophilized cake or powder to be administered by intravenous injection upon reconstitution with Sterile Water for Injection, USP.
- Administration of a pharmaceutical composition of the invention is not limited to any particular delivery system and may include, without limitation, parenteral (including subcutaneous, intravenous, intracranial, intramedullary, intraarticular, intramuscular, intrathecal, or intraperitoneal injection), transdermal, or oral (for example, in capsules, suspensions, or tablets). Administration to an individual may occur in a single dose or in repeat administrations, and in any of a variety of physiologically acceptable salt forms, and/or with an acceptable pharmaceutical carrier and/or additive as part of a pharmaceutical composition.
- the conjugates described herein are administered in therapeutically effective amounts.
- a therapeutically effective amount may vary with the subject's age, condition, and sex, as well as the severity of the medical condition in the subject.
- the dosage may be determined by a physician and adjusted, as necessary, to suit observed effects of the treatment. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in vitro (i.e., cell cultures) or in vivo (i.e., experimental animal models), e.g., for determining the LD 50 (the dose lethal to 50% of the population) and the ED 50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index (or therapeutic ratio), and can be expressed as the ratio LD 50 /ED 50 .
- Conjugates that exhibit therapeutic indices of at least 1 , 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 are described herein. Conjugates that exhibit a large therapeutic index are preferred.
- the data obtained from in vitro assays and animal studies, for example, can be used in formulating a range of dosage for use in humans.
- the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED 50 with low, little, or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from in vitro assays.
- a dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC 50 (i.e., the concentration of the test conjugate which achieves a half-maximal inhibition of symptoms) as determined in in vitro experiments.
- Levels in plasma may be measured, for example, by high performance liquid chromatography or by an appropriate enzymatic activity assay.
- the effects of any particular dosage can be monitored by a suitable bioassay of endpoints.
- conjugates of the invention may be administered at a dose of approximately from 1 ⁇ g/kg to 500 mg/kg, depending on the severity of the symptoms and the progression of the disease.
- proteinaceous compounds may be administered by slow intravenous infusion in an outpatient setting every, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, or more days, or by, e.g., weekly, biweekly, monthly, or bimonthly administration.
- the appropriate therapeutically effective dose of a compound is selected by a treating clinician and would range approximately from 1 ⁇ g/kg to 500 mg/kg, from 1 ⁇ g/kg to 10 mg/kg, from 1 ⁇ g/kg to 1 mg/kg, from 10 ⁇ g/kg to 1 mg/kg, from 10 ⁇ g/kg to 100 ⁇ g/kg, from 100 ⁇ g to 1 mg/kg, and from 500 ⁇ g/kg to 5 mg/kg.
- conjugates of ⁇ -galactosidase A may be administered by intravenous infusion at a dose of, e.g., 1.0 mg/kg body weight every two weeks at an infusion rate of, e.g., less than or equal to 10, 13, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, or 33 mg/hour).
- conjugates of ⁇ -glucosidase may be administered intravenous injection at a dose of, e.g., 20 mg/kg or 40 mg/kg every two weeks, over approximately, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9, or 10 hours.
- the rate of administration of ⁇ -glucosidase may be started at, e.g., 1 mg/kg/hr and then increased by, e.g., 2 mg/kg/hr every 30 minutes, after establishing patient tolerance to the infusion rate, until a maximum of, e.g., 7 mg/kg/hr.
- examples of specific dosages may be found in the Physicians' Desk Reference ® .
- the invention provides methods of treating lysosomal storage disorders, such as, e.g., those disclosed in Table 1.
- the invention provides the use of a conjugate described herein for treating a lysosomal storage disorder in a subject in need thereof.
- the invention further provides methods of targeting proteins to the lysosome by conjugation with oligosaccharides comprising mannose-6-phosphate.
- the method comprises administering to a mammal having a lysosomal storage disorder an oligosaccharide-glycoprotein conjugate of the invention in a therapeutically effective amount.
- the oligosaccharide-glycoprotein conjugate may be a conjugate of a lysosomal enzyme, such as a lysosomal enzyme listed in Table 1 , with an oligosaccharide comprising mannose-6-phosphate.
- the method comprises administering to a subject in need thereof a pharmaceutical composition comprising at least one of the conjugates described herein.
- conjugates of the invention may be administered with one or more other therapies.
- the one or more other therapies may be administered concurrently with (including concurrent administration as a combined formulation), before, or after the administration of the conjugates of the invention.
- a patient may be treated (before, after, or during treatment with a conjugate of the invention) with an antipyretic, antihistamine, and/or immunosuppressant.
- a patient may be treated with an antipyretic, antihistamine, and/or immunosuppressant prior to treatment with an oligosaccharide-glycoprotein conjugate of the invention in order to decrease or prevent infusion associated reactions.
- patients may be pretreated with one or more of acetaminophen, azathioprine, cyclophosphamide, cyclosporin A, methotrexate, mycophenolate mofetil, oral steroids, or rapamycin.
- methotrexate e.g., with 0.1 , 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1 , 2, 3, 4, 5, 6, 8, 10, 12, 15, 25, 30, 35, 40, 50, 60, 70, 80 mg/kg methotrexate, or more
- immune tolerance toward conjugates of the invention may be induced in a patient with a lysosomal storage disorder such as, e.g., mucopolysaccharidosis I, by treatment with cyclosporin A and azathioprine.
- a lysosomal storage disorder such as, e.g., mucopolysaccharidosis I
- the patient may be treated with cyclosporine A and azathioprine as described in Kakkis et al., Proc. Natl. Acad. ScL U.S.A. 101 :829-834 (2004).
- a patient may be treated (before, after, or during treatment with a conjugate of the invention) with e.g., small molecule therapy and/or gene therapy, including small molecule therapy and gene therapy directed toward treatment of a lysosomal storage disorder.
- Small molecule therapy may comprise administration of one or more compounds described in, e.g., U.S. Patent Application Publication Nos. 2003/0050299, 2003/0153768; 2005/0222244; and 2005/0267094.
- Gene therapy may be performed as described in, e.g., U.S. Patent Nos. 5,952,516; 6,066,626; 6,071 ,890; and 6,287,857 and U.S. Patent Application Publication No. 2003/0087868.
- treatment refers to both therapeutic treatment and prophylactic/preventative measures.
- those in need of treatment may include individuals already having a particular lysosomal storage disease as well as those at risk for the disease (i.e., those who are likely to ultimately acquire the disorder or certain symptoms of the disorder).
- a therapeutic method results in the prevention or amelioration of symptoms or an otherwise desired biological outcome, and may be evaluated by improved clinical signs or delayed onset of disease, increased activity of the metabolically defective enzyme, and/or decreased levels of the accumulated substrate of the metabolically defective enzyme.
- the conjugates of the present invention are useful to treat various lysosomal storage disorders in humans or animals.
- administration of the conjugates can be used to increase the deficient enzymatic activity in a patient, for example, by at least 10%.
- the increased enzymatic activity may be determined by, e.g., a reduction in clinical symptoms or by an appropriate clinical or biological assay.
- GAA conjugates may be administered for the treatment of Pompe disease (also known as acid ⁇ -glucosidase deficiency, acid maltase deficiency, glycogen storage disease type II, glycogenosis II, and lysosomal ⁇ - glucosidase deficiency).
- Increased GAA activity may be determined by biochemical (see, e.g., Zhu et al., J. Biol. Chem. 279: 50336-50341 (2004)) or histological observation of reduced lysosomal glycogen accumulation in, e.g., cardiac myocytes, skeletal myocytes, or skin fibroblasts.
- GAA activity may also be assayed in, e.g., a muscle biopsy sample, in cultured skin fibroblasts, in lymphocytes, and in dried blood spots. Dried blood spot assays are described in e.g., Umpathysivam et al., CHn. Chem. 47:1378-1383 (2001) and Li et al., Clin. Chem. 50:1785-1796 (2004).
- Treatment of Pompe disease may also be assessed by, e.g., serum levels of creatinine kinase, gains in motor function (e.g., as assessed by the Alberta Infant Motor Scale), changes in left ventricular mass index as measured by echocardiogram, and cardiac electrical activity, as measured by electrocardiogram.
- GAA conjugates may result in a reduction in one or more symptoms of Pompe disease such as cardiomegaly, cardiomyopathy, daytime somnoiescence, exertional dyspnea, failure to thrive, feeding difficulties, "floppiness," gait abnormalities, headaches, hypotonia, organomegaly (e.g., enlargement of heart, tongue, liver), lordosis, loss of balance, lower back pain, morning headaches, muscle weakness, respiratory insufficiency, scapular winging, scoliosis, reduced deep tendon reflexes, sleep apnea, susceptibility to respiratory infections, and vomiting.
- Pompe disease such as cardiomegaly, cardiomyopathy, daytime somnoiescence, exertional dyspnea, failure to thrive, feeding difficulties, "floppiness,” gait abnormalities, headaches, hypotonia, organomegaly (e.g., enlargement of heart, tongue, liver), lordosis, loss of balance, lower back pain, morning headaches, muscle weakness,
- conjugates of ⁇ -galactosidase A with oligosaccharides comprising M6P are administered for the treatment of Fabry disease.
- Fabry disease or Anderson-Fabry disease, is a rare, X-linked, lysosomal storage disorder marked by a deficiency of ⁇ -galactosidase A, and results in accumulation of giobotriaosylceramide (GL3) and other neutral glycosphingolipids in the lysosomes of visceral tissues and endothelial, perithelia!, and muscle cells. Accumulation of the neutral glycosphingolipids in the vasculature results in narrowing and dilatation of the blood vessels, and ultimately to ischemia and infaraction.
- GL3 giobotriaosylceramide
- ⁇ -galactosidase A conjugates may result in a reduction in one or more clinical symptoms of Fabry disease including, e.g., acroparesthesia, angina, angiokeratoma, arrythmia, ataxia of gait, burning and/or tingling pain in the hands and feet, cataracts, cold intolerance, conduction abnormalities, corneal whorling, coronary artery disease, dementia, depression, diarrhea, dilated cardiac chambers, dizziness, cardiomegaly, cardiomyopathy, diplopia, dysarthria, fatigue, fever with elevated erythrocyte sedimentation rate, hearing problems, heart disease, heart valve problems, heat intolerance, hemiataxia, hemiparesis, hypohidrosis, impaired sweating, infaraction, ischemia, joint pain, kidney disease, left ventricular hypertrophy, lenticular abnormalities, lenticular opacity, lipiduria, muscle weakness, myocardial infarction, nausea,
- Administration of ⁇ -galactosidase A conjugates may result in increased ⁇ -galactosidase A activity in, e.g., plasma, tears, leukocytes, biopsied tissues, or cultured skin fibroblasts.
- Administration of ⁇ -galactosidase A conjugates may also result in a histologic finding of a reduction (e.g., of at least 10%) or lack of increase of birefringent lipid globules. It may also result in a decrease in lipid globules in urinary sediment, improved renal function as measured by serum creatinine levels or creatinine clearance, and reduced proteinuria.
- ⁇ -galactosidase A conjugates may also result in a reduction in GL3 inclusions in the capillary endothelium of the kidney, heart, and skin. Additional assays for measuring efficacy of treatment for Fabry disease can be found in, e.g., MacDermott et al., J. Med. Genet. 38:750-760 (2001).
- conjugates of acid sphingomyelinase are administered for treatment of Niemann-Pick disease, or acid sphingomyelinase deficiency.
- Administration of acid sphingomyelinase conjugates may result in a reduction in one or more clinical symptoms of Niemann-Pick disease including, e.g., abnormal cholesterol levels, abnormal lipid levels, ataxia, blood abnormalities, cherry red spots in the eye, frequent lung infections, growth retardation, hepatosplenomegaly, low numbers of platelets, lymphadenopathy, peripheral neuropathy, problems with lung function, shortness of breath, skin pigmentation changes, or xanthomas.
- conjugates may be administered intracranially.
- An alternative embodiment relates to treatment of mucopolysaccharidosis I (including, e.g., Hurler and Hurler-Scheie forms of MPS I) with conjugates comprising ⁇ -L-iduronidase.
- Administration of ⁇ -L-iduronidase conjugates may result in a reduction in one or more clinical symptoms of MPS I including, e.g., aortic regurgitation, aortic stenosis, carpal tunnel syndrome, chronic rhinitis, conductive hearing loss, constipation, corneal clouding, developmental delay, diarrhea, distended abdomen, dorsolumbar kyphosis, gibbus deformity of the back, hepatosplenomegaly, hydrocephalus, inguinal hernia, kyphosis, mental retardation, mitral regurgitation, mitral stenosis, night- blindness, open-angle glaucoma, poor hand function, progressive arthropathy, recurrent respiratory infections, respiratory insufficiency
- Examples 1 -4 below describe the synthetic route depicted in FIG. 1.
- Compounds 1 , 2, 3, and 4, as used below, have the chemical structures depicted in FIG. 1.
- 100 mg of t-Boc- aminooxy acetic acid tetrafluorophenyl ester 2 (Invitrogen Corp.; Carlsbad, CA; catalog # B3030) was dissolved in 7.5 ml of DMSO.
- Method A The reaction mixture was diluted with an equal volume of H 2 O and dialyzed in dialysis tubing with molecular weight cutoff of 1000 Dalton (SpectraPor Inc.) twice against 4 L of H 2 O at 4 e C for at least 3 hours each. The samples were then lyophilized.
- Method B A Sephadex G-10 gel permeation chromatography column with a bed volume of 225 ml was packed and equilibrated with deionized water. The reaction mixture was loaded onto the column, drained by gravity, and then eluted with deionized water at a flow rate of 75 ml per hour. 4.5 ml fractions were collected with a fraction collector.
- Fractions 10-23 which contained oligosaccharide 3, were collected, combined and lyophilized.
- the other small molecules including t-Boc-AOAA, DHBt-OH, and DMSO, eluted in the later fractions, and were discarded.
- t-Boc group of the lyophilized sample was deprotected in 5 ml of 50% trifluoroacetic acid (TFA) in dicholormethane (DCM) in a glass bottle for 30 min with gentle shaking at 100 RPM.
- TFA/DCM was then removed by a stream of N 2 in a chemical hood.
- Method A After removing the TFA/DCM, the residue was dissolved in 10 ml of 0.5 M sodium acetate buffer, pH 5, and transferred to dialysis tubing with a molecular weight cutoff of 1000 Dalton. The bottle was washed with 4 ml of the same buffer, which was then transferred to the dialysis tubing. The sample was dialyzed twice against 3 L of 25 mM sodium acetate buffer, pH 7, for at least 3 hours, and then transferred to 4 L ice-cold H 2 O for overnight dialysis. The sample was recovered from the dialysis tubing and lyophilized.
- Method B After removing the TFA/DCM, the residue was dissolved in 5 ml of 0.5 M sodium acetate buffer, pH 7.5, and loaded onto a Sephadex G-10 gel permeation chromatography column as in Example 2, Method B. The reaction mixture was loaded onto the column, drained by gravity, and then eluted with deionized water at a flow rate of 75 ml per hour. 4.5 ml fractions were collected with a fraction collector. Fractions 10-23, which contained purified oligosaccharide 4, were collected and lyophilized. A higher yield of oligosaccharide 4 was obtained upon purification by Method B than by Method A.
- rhGAA Lyophilized recombinant human GAA
- rhGAA Lyophilized recombinant human GAA
- 4 L 100 mM acetate buffer (pH 5.6) 4 times to completely remove mannitol.
- the rhGAA was oxidized with 7.5 mM sodium periodate from 100 mM stock in 100 mM acetate buffer.
- glycerol was added, and the sample was mixed on ice for 10 minutes to decompose excess sodium periodate.
- the oxidized material was then dialyzed against aqueous buffer (e.g., 100 mM sodium acetate) overnight.
- aqueous buffer e.g., 100 mM sodium acetate
- Detection of M6P The extent of oligosaccharide conjugation was measured by assaying conjugate 5 for binding to a M6P receptor column to which glycoproteins lacking M6P do not bind. Five micrograms of conjugate 5 were loaded onto a pre-equilibrated CI-MPR-Sepharose column (the column was prepared by coupling CI-MPR isolated from fetal bovine serum to Affigel-10), which was then washed with CI-MPR binding buffer for 11x 2 ml_ fractions and eluted with CI-MPR binding buffer containing 5 mM M6P for 7x 2mL fractions. A total of 18 fractions were collected and assayed for enzymatic activity.
- Conjugate 5 is treated with 4N trifluoroacetic acid to hydrolyze the oligosaccharides, followed by high pH anion exchange chromatography with pulsed amperometric detection (PAD) on a BioLC liquid chromatography system (Dionex).
- PAD pulsed amperometric detection
- the monosaccharide content is extrapolated from a monosaccharide standard curve using premixed monosaccharide standards (Dionex).
- GAA activity is measured using a fluorometric assay in black 96-well microplates using 4-methylumbelliferyl- ⁇ -D-glucoside as a substrate. Dilutions of conjugate 5 are added in triplicate to a microtiter plate. 4-methylumbelliferyl- ⁇ -D-glucoside is added to each sample. The 96-well plate is incubated in a 37 0 C incubator for 30 minutes. The release of product is detected fluorometrically, and compared to standard curves generated by measuring the fluorescence of a known quantity of a standard. The reaction is quenched by the addition of 125 ⁇ l_ of 1.0 M glycine-carbonate buffer, pH 10.5 to all wells. The specific activity is defined as nmol product released/hr/mg.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
Description
Claims
Priority Applications (25)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL243117A IL243117B2 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
US12/523,631 US8759501B2 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
CA2675968A CA2675968C (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
JP2009546533A JP5999867B2 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides containing aminooxy groups and conjugates thereof |
PL11188504T PL2457919T3 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
EP11188504.2A EP2457919B1 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
SI200830995T SI2121713T1 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
EP23187944.6A EP4293112A3 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
DK08727910.5T DK2121713T3 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides, comprising an amino group and conjugates thereof |
EP19177425.6A EP3597655B1 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
PL08727910T PL2121713T3 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
ES08727910T ES2417146T3 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminoxy group and conjugates thereof |
CN2008800076802A CN101631794B (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
EP08727910.5A EP2121713B1 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
IL199925A IL199925A (en) | 2007-01-18 | 2009-07-16 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
IL222792A IL222792A0 (en) | 2007-01-18 | 2012-11-01 | Method of coupling an oligosaccharide to a protein, oligosaccharide-protein conjugates, uses thereof and pharmaceutical compositions comprising the same |
HRP20130744AT HRP20130744T1 (en) | 2007-01-18 | 2013-08-06 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
US14/272,960 US9469850B2 (en) | 2007-01-18 | 2014-05-08 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
US15/280,864 US20170014520A1 (en) | 2007-01-18 | 2016-09-29 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
US16/268,989 US10907142B2 (en) | 2007-01-18 | 2019-02-06 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
CY20191100928T CY1122452T1 (en) | 2007-01-18 | 2019-09-04 | OLIGOSACCHARITES CONTAINING AN AMINO ACID GROUP AND THEIR CONJUGATIONS |
US17/472,367 US20220204963A1 (en) | 2007-01-18 | 2021-09-10 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
NO2022056C NO2022056I1 (en) | 2007-01-18 | 2022-12-09 | avalglucosidase alfa |
FR22C1061C FR22C1061I2 (en) | 2007-01-18 | 2022-12-15 | OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF |
NL301210C NL301210I2 (en) | 2007-01-18 | 2022-12-16 | Avalglucosidase alpha |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US88547107P | 2007-01-18 | 2007-01-18 | |
US60/885,471 | 2007-01-18 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/523,631 A-371-Of-International US8759501B2 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
US14/272,960 Continuation US9469850B2 (en) | 2007-01-18 | 2014-05-08 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2008089403A2 true WO2008089403A2 (en) | 2008-07-24 |
WO2008089403A3 WO2008089403A3 (en) | 2008-11-13 |
Family
ID=39473250
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2008/051429 WO2008089403A2 (en) | 2007-01-18 | 2008-01-18 | Oligosaccharides comprising an aminooxy group and conjugates thereof |
Country Status (20)
Country | Link |
---|---|
US (5) | US8759501B2 (en) |
EP (5) | EP3597655B1 (en) |
JP (6) | JP5999867B2 (en) |
CN (2) | CN101631794B (en) |
CA (1) | CA2675968C (en) |
CY (2) | CY1119954T1 (en) |
DK (3) | DK2121713T3 (en) |
ES (3) | ES2656314T3 (en) |
FI (1) | FIC20220047I1 (en) |
FR (1) | FR22C1061I2 (en) |
HR (3) | HRP20130744T1 (en) |
HU (3) | HUE036140T2 (en) |
IL (3) | IL243117B2 (en) |
LT (2) | LT2457920T (en) |
NL (1) | NL301210I2 (en) |
NO (2) | NO2457920T3 (en) |
PL (3) | PL2121713T3 (en) |
PT (3) | PT2457920T (en) |
SI (2) | SI2457920T1 (en) |
WO (1) | WO2008089403A2 (en) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009024977A2 (en) * | 2007-08-20 | 2009-02-26 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
WO2010075010A2 (en) | 2008-12-16 | 2010-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
JP2013500375A (en) * | 2009-07-27 | 2013-01-07 | リポクセン テクノロジーズ リミテッド | Glycopolysial oxidation of non-blood clotting proteins |
US8399657B2 (en) | 2001-01-18 | 2013-03-19 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
US8759501B2 (en) | 2007-01-18 | 2014-06-24 | Genzyme Corporation | Oligosaccharides comprising an aminooxy group and conjugates thereof |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
JP2016113626A (en) * | 2009-07-27 | 2016-06-23 | リポクセン テクノロジーズ リミテッド | Glycopolysialylation of non-blood coagulation protein |
US9732333B2 (en) | 2011-01-20 | 2017-08-15 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
WO2021159092A1 (en) | 2020-02-08 | 2021-08-12 | Genzyme Corporation | Compositions and methods for treating pompe disease |
WO2021156792A1 (en) | 2020-02-07 | 2021-08-12 | Novartis Ag | Targeted plasma protein degradation |
US11103596B2 (en) | 2015-05-11 | 2021-08-31 | Ucl Business Plc | Fabry disease gene therapy |
WO2021257409A1 (en) | 2020-06-14 | 2021-12-23 | Genzyme Corporation | Compositions and methods for treating late-onset pompe disease |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008013735A2 (en) * | 2006-07-21 | 2008-01-31 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid |
WO2011000958A1 (en) | 2009-07-03 | 2011-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
EP2585096B1 (en) * | 2010-06-24 | 2021-05-05 | University Of Kansas | Bifunctional conjugate compositions and associated methods |
WO2012082635A1 (en) * | 2010-12-13 | 2012-06-21 | Ancora Pharmaceuticals, Inc. | Synthetic oligosaccharide group a streptococcus |
AU2014218854B2 (en) | 2013-02-20 | 2019-01-24 | Valerion Therapeutics, Llc | Methods and compositions for treatment of Pompe disease |
TWI821227B (en) | 2017-12-22 | 2023-11-11 | 美商健臻公司 | Biomarkers of methotrexate-induced immune tolerance |
SG11202104207TA (en) * | 2018-11-08 | 2021-05-28 | Kaleido Biosciences Inc | Oligosaccharide compositions and methods of use thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137125A1 (en) | 2001-01-18 | 2002-09-26 | Yunxiang Zhu | Methods for introducing mannose 6-phosphate and other oligosacharides onto glycoroteins and its application thereof |
US20050169941A1 (en) | 2004-01-29 | 2005-08-04 | Andrew Lees | Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines |
Family Cites Families (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4701521A (en) * | 1978-07-17 | 1987-10-20 | The Trustees Of Boston University | Method of effecting cellular uptake of molecules |
DE2940845B1 (en) | 1979-10-09 | 1980-06-26 | Ford Werke Ag | Centrifugal pump seal, in particular for cooling water pumps in motor vehicles |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US5066789A (en) * | 1988-09-30 | 1991-11-19 | Neorx Corporation | Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages |
US5206370A (en) * | 1989-02-24 | 1993-04-27 | Johnson Matthey, Inc. | Certain pyridyl hydrazines and hydrazides useful for protein labeling |
IL93432A (en) | 1989-02-24 | 1994-02-27 | Johnson Mathey Inc | Hydrazines and hydrazides, their conjugates with macromolecules and such conjugates labelled with metal ions |
US5280113A (en) * | 1989-08-16 | 1994-01-18 | Monsanto Company | Method for producing synthetic N-linked glycoconjugates |
US5212298A (en) * | 1989-08-16 | 1993-05-18 | Monsanto Company | Method for producing synthetic N-linked glycoconjugates |
US5324663A (en) * | 1990-02-14 | 1994-06-28 | The Regents Of The University Of Michigan | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures |
US5583042A (en) * | 1990-04-16 | 1996-12-10 | Neose Pharmaceuticals, Inc. | Apparatus for the synthesis of saccharide compositions |
US5153312A (en) * | 1990-09-28 | 1992-10-06 | American Cyanamid Company | Oligosaccharide conjugate vaccines |
US5492821A (en) * | 1990-11-14 | 1996-02-20 | Cargill, Inc. | Stabilized polyacrylic saccharide protein conjugates |
WO1992016212A1 (en) * | 1991-03-13 | 1992-10-01 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Increasing the therapeutic efficiency of macrophage-targeted therapeutic agents by up-regulating the mannose lectin on macrophages |
WO1992016555A1 (en) | 1991-03-18 | 1992-10-01 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
FR2721612B1 (en) * | 1994-06-23 | 1996-08-09 | Idm | New oligoside derivatives, their preparation process and their applications. |
US6132764A (en) * | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
US6071890A (en) | 1994-12-09 | 2000-06-06 | Genzyme Corporation | Organ-specific targeting of cationic amphiphile/DNA complexes for gene therapy |
US6118045A (en) * | 1995-08-02 | 2000-09-12 | Pharming B.V. | Lysosomal proteins produced in the milk of transgenic animals |
AUPO190596A0 (en) * | 1996-08-26 | 1996-09-19 | Alchemia Pty Ltd | Oligosaccharide synthesis |
ES2335557T3 (en) * | 1997-01-21 | 2010-03-29 | Sanofi Pasteur | CONJUGATES OF PEPTIDO-POLISACARIDO. |
US5952516A (en) | 1997-05-08 | 1999-09-14 | Genzyme Corporation | Cationic amphiphiles containing multiplesteroid lipophilic groups |
EP2147681A1 (en) | 1997-10-29 | 2010-01-27 | Genzyme Corporation | Compositions and methods for treating lysosomal storage disease |
US6287857B1 (en) | 1998-02-09 | 2001-09-11 | Genzyme Corporation | Nucleic acid delivery vehicles |
US6538117B1 (en) * | 1999-08-10 | 2003-03-25 | The Scripps Research Institute | Programmable one-pot oligosaccharide synthesis |
EP1109576B1 (en) * | 1998-08-19 | 2009-10-21 | Baxter Healthcare SA | Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide |
US6399575B1 (en) * | 1998-11-10 | 2002-06-04 | Auburn University | Methods and compositions for targeting compounds to the central nervous system |
EP1035137A1 (en) * | 1999-03-12 | 2000-09-13 | Pasteur Merieux Serums Et Vaccins | Method for the reductive amination of polysaccharides |
CA2376057A1 (en) * | 1999-06-08 | 2000-12-14 | La Jolla Pharmaceutical Company | Valency platform molecules comprising aminooxy groups |
US6770468B1 (en) * | 1999-09-14 | 2004-08-03 | Genzyme Glycobiology Research Institute, Inc. | Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway |
US6537785B1 (en) * | 1999-09-14 | 2003-03-25 | Genzyme Glycobiology Research Institute, Inc. | Methods of treating lysosomal storage diseases |
US6749865B2 (en) * | 2000-02-15 | 2004-06-15 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
WO2001060412A2 (en) | 2000-02-15 | 2001-08-23 | Genzyme Corporation | Modification of biopolymers for improved drug delivery |
AU2001280035A1 (en) | 2000-07-26 | 2002-02-05 | Ramot University Authority For Applied Research And Industrial Development Ltd. | Intracellular delivery system for protein phosphatases and other polypeptides |
EP1315559B1 (en) * | 2000-08-18 | 2006-03-22 | Massachusetts Institute Of Technology | Apparatus and methods for the automated synthesis of oligosaccharides |
US6676963B1 (en) * | 2000-10-27 | 2004-01-13 | Barnes-Jewish Hospital | Ligand-targeted emulsions carrying bioactive agents |
US7723296B2 (en) * | 2001-01-18 | 2010-05-25 | Genzyme Corporation | Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
US7560424B2 (en) * | 2001-04-30 | 2009-07-14 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
US7629309B2 (en) * | 2002-05-29 | 2009-12-08 | Zystor Therapeutics, Inc. | Targeted therapeutic proteins |
EP1974752B1 (en) * | 2001-04-30 | 2012-09-26 | BioMarin Pharmaceutical Inc. | Subcellular targeting of therapeutic proteins |
AU2001260526A1 (en) | 2001-05-07 | 2001-12-03 | Supratek Pharma, Inc. | A ligand for enhancing oral and cns delivery of biological agents |
PT2266968E (en) | 2001-07-16 | 2013-02-25 | Genzyme Corp | Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors |
US7265084B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
CN102180944A (en) | 2001-10-10 | 2011-09-14 | 诺和诺德公司 | Remodeling and glycoconjugation of peptides |
WO2003045928A1 (en) | 2001-11-26 | 2003-06-05 | Genzyme Corporation | Diastereoselective synthesis of udp-glucose : n-acylsphingosine glucosyltransferase inhibitors |
US6905856B2 (en) * | 2001-12-21 | 2005-06-14 | Genzyme Glycobiology Research Institute, Inc. | Soluble GlcNAc phosphotransferase |
US6800472B2 (en) * | 2001-12-21 | 2004-10-05 | Genzyme Glycobiology Research Institute, Inc. | Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase |
EP1463512B1 (en) | 2002-01-11 | 2014-05-28 | biOasis Technologies Inc. | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes |
TWI295483B (en) | 2002-01-31 | 2008-04-01 | Sumitomo Chemical Co | 3-5 group compound semiconductor, process for producing the same, and compound semiconductor element using the same |
WO2003070823A2 (en) * | 2002-02-20 | 2003-08-28 | The General Hospital Corporation | Conjugates comprising a biodegradable polymer and uses therefor |
US6916802B2 (en) | 2002-04-29 | 2005-07-12 | Genzyme Corporation | Amino ceramide-like compounds and therapeutic methods of use |
BR0314107A (en) | 2002-09-11 | 2005-07-19 | Fresenius Kabi De Gmbh | Production method of hydroxyalkyl starch derivatives |
EP1400533A1 (en) * | 2002-09-11 | 2004-03-24 | Fresenius Kabi Deutschland GmbH | HASylated polypeptides, especially HASylated erythropoietin |
US20050026823A1 (en) * | 2003-06-20 | 2005-02-03 | Biomarin Pharmaceutical Inc. | Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues |
WO2005002515A2 (en) | 2003-06-20 | 2005-01-13 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
JP2007501811A (en) | 2003-08-08 | 2007-02-01 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Use of galactose oxidase for selective chemical conjugation of a retarder molecule to a protein of therapeutic interest. |
ES2294535T3 (en) | 2003-08-12 | 2008-04-01 | Lipoxen Technologies Limited | DERIVATIVES OF POLISIALIC ACID. |
US7442372B2 (en) | 2003-08-29 | 2008-10-28 | Biomarin Pharmaceutical Inc. | Delivery of therapeutic compounds to the brain and other tissues |
EP1525890A1 (en) | 2003-10-02 | 2005-04-27 | Complex Biosystems GmbH | Protein-Proteophore complexes |
US7176185B2 (en) * | 2003-11-25 | 2007-02-13 | Tsrl, Inc. | Short peptide carrier system for cellular delivery of agent |
CA2556245A1 (en) | 2004-02-06 | 2005-08-25 | Biomarin Pharmaceutical Inc. | Manufacture of highly phosphorylated lysosomal enzymes and uses thereof |
EP1740204B1 (en) | 2004-04-01 | 2018-03-14 | Chiesi Farmaceutici S.p.A. | Medicinal use of alpha-mannosidase |
US8017151B2 (en) * | 2004-09-07 | 2011-09-13 | Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center | Amphiphilic polymer-protein conjugates and methods of use thereof |
PL1877099T3 (en) | 2005-04-06 | 2013-02-28 | Genzyme Corp | Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety |
WO2008089339A2 (en) | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharide conjugates for cellular targeting |
WO2008089403A2 (en) | 2007-01-18 | 2008-07-24 | Genzyme Corporation | Oligosaccharides comprising an aminooxy group and conjugates thereof |
CN105879047A (en) * | 2008-12-16 | 2016-08-24 | 建新公司 | Oligosaccharide-protein conjugates |
-
2008
- 2008-01-18 WO PCT/US2008/051429 patent/WO2008089403A2/en active Application Filing
- 2008-01-18 PT PT111885067T patent/PT2457920T/en unknown
- 2008-01-18 EP EP19177425.6A patent/EP3597655B1/en active Active
- 2008-01-18 DK DK08727910.5T patent/DK2121713T3/en active
- 2008-01-18 NO NO11188506A patent/NO2457920T3/no unknown
- 2008-01-18 PL PL08727910T patent/PL2121713T3/en unknown
- 2008-01-18 PL PL11188506T patent/PL2457920T3/en unknown
- 2008-01-18 PT PT11188504T patent/PT2457919T/en unknown
- 2008-01-18 EP EP23187944.6A patent/EP4293112A3/en active Pending
- 2008-01-18 CN CN2008800076802A patent/CN101631794B/en active Active
- 2008-01-18 PT PT87279105T patent/PT2121713E/en unknown
- 2008-01-18 DK DK11188506.7T patent/DK2457920T3/en active
- 2008-01-18 HU HUE11188506A patent/HUE036140T2/en unknown
- 2008-01-18 EP EP11188504.2A patent/EP2457919B1/en active Active
- 2008-01-18 ES ES11188506.7T patent/ES2656314T3/en active Active
- 2008-01-18 EP EP08727910.5A patent/EP2121713B1/en active Active
- 2008-01-18 CA CA2675968A patent/CA2675968C/en not_active Expired - Fee Related
- 2008-01-18 US US12/523,631 patent/US8759501B2/en active Active
- 2008-01-18 SI SI200831908T patent/SI2457920T1/en unknown
- 2008-01-18 DK DK11188504.2T patent/DK2457919T3/en active
- 2008-01-18 LT LTEP11188506.7T patent/LT2457920T/en unknown
- 2008-01-18 EP EP11188506.7A patent/EP2457920B1/en active Active
- 2008-01-18 CN CN201210469389.5A patent/CN102978185B/en active Active
- 2008-01-18 ES ES08727910T patent/ES2417146T3/en active Active
- 2008-01-18 ES ES11188504T patent/ES2744574T3/en active Active
- 2008-01-18 LT LTEP11188504.2T patent/LT2457919T/en unknown
- 2008-01-18 IL IL243117A patent/IL243117B2/en unknown
- 2008-01-18 PL PL11188504T patent/PL2457919T3/en unknown
- 2008-01-18 HU HUE11188504A patent/HUE045046T2/en unknown
- 2008-01-18 SI SI200832088T patent/SI2457919T1/en unknown
- 2008-01-18 JP JP2009546533A patent/JP5999867B2/en active Active
-
2009
- 2009-07-16 IL IL199925A patent/IL199925A/en active IP Right Grant
-
2012
- 2012-11-01 IL IL222792A patent/IL222792A0/en active IP Right Grant
-
2013
- 2013-08-06 HR HRP20130744AT patent/HRP20130744T1/en unknown
-
2014
- 2014-05-08 US US14/272,960 patent/US9469850B2/en active Active
- 2014-10-03 JP JP2014204593A patent/JP6039625B2/en active Active
-
2016
- 2016-09-29 US US15/280,864 patent/US20170014520A1/en not_active Abandoned
- 2016-11-02 JP JP2016214773A patent/JP6309592B2/en active Active
-
2018
- 2018-01-16 HR HRP20180076TT patent/HRP20180076T1/en unknown
- 2018-01-24 CY CY20181100094T patent/CY1119954T1/en unknown
- 2018-03-13 JP JP2018044959A patent/JP2018109194A/en active Pending
-
2019
- 2019-02-06 US US16/268,989 patent/US10907142B2/en active Active
- 2019-08-30 HR HRP20191562 patent/HRP20191562T1/en unknown
- 2019-09-04 CY CY20191100928T patent/CY1122452T1/en unknown
-
2020
- 2020-08-07 JP JP2020134331A patent/JP2020185011A/en active Pending
-
2021
- 2021-09-10 US US17/472,367 patent/US20220204963A1/en not_active Abandoned
-
2022
- 2022-07-15 JP JP2022113593A patent/JP2022137232A/en active Pending
- 2022-12-09 NO NO2022056C patent/NO2022056I1/en unknown
- 2022-12-12 FI FIC20220047C patent/FIC20220047I1/en unknown
- 2022-12-15 FR FR22C1061C patent/FR22C1061I2/en active Active
- 2022-12-16 NL NL301210C patent/NL301210I2/en unknown
- 2022-12-19 HU HUS2200055C patent/HUS2200055I1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020137125A1 (en) | 2001-01-18 | 2002-09-26 | Yunxiang Zhu | Methods for introducing mannose 6-phosphate and other oligosacharides onto glycoroteins and its application thereof |
US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
US20050169941A1 (en) | 2004-01-29 | 2005-08-04 | Andrew Lees | Use of amino-oxy functional groups in the preparation of protein-polysaccharide conjugate vaccines |
Cited By (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973887B2 (en) | 2001-01-18 | 2021-04-13 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
US10363291B2 (en) | 2001-01-18 | 2019-07-30 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins and applications thereof |
US9687531B2 (en) | 2001-01-18 | 2017-06-27 | Genzyme Corporation | Methods for introducing mannose 6 phosphate and other oligosaccharides onto glycoproteins and applications thereof |
US8399657B2 (en) | 2001-01-18 | 2013-03-19 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins and its application thereof |
US8841427B2 (en) | 2001-01-18 | 2014-09-23 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins and applications thereof |
US8759501B2 (en) | 2007-01-18 | 2014-06-24 | Genzyme Corporation | Oligosaccharides comprising an aminooxy group and conjugates thereof |
US10907142B2 (en) | 2007-01-18 | 2021-02-02 | Genzyme Corporation | Oligosaccharides comprising an aminooxy group and conjugates thereof |
US9469850B2 (en) | 2007-01-18 | 2016-10-18 | Genzyme Corporation | Oligosaccharides comprising an aminooxy group and conjugates thereof |
WO2009024977A3 (en) * | 2007-08-20 | 2010-01-28 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
WO2009024977A2 (en) * | 2007-08-20 | 2009-02-26 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
US8742079B2 (en) | 2007-08-20 | 2014-06-03 | Protalix Ltd. | Saccharide-containing protein conjugates and uses thereof |
JP2017008098A (en) * | 2008-12-16 | 2017-01-12 | ジェンザイム・コーポレーション | Oligosaccharide-protein conjugates |
WO2010075010A3 (en) * | 2008-12-16 | 2011-01-06 | Genzyme Corporation | Oligosaccharide-protein conjugates |
US8835614B2 (en) | 2008-12-16 | 2014-09-16 | Genzyme Corporation | Oligosaccharide-protein conjugates |
CN103432566A (en) * | 2008-12-16 | 2013-12-11 | 建新公司 | Oligosaccharide-protein conjugates |
EP2889043A2 (en) | 2008-12-16 | 2015-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
EP2889043A3 (en) * | 2008-12-16 | 2015-07-22 | Genzyme Corporation | Oligosaccharide-protein conjugates |
EP4212541A1 (en) | 2008-12-16 | 2023-07-19 | Genzyme Corporation | Oligosaccharide-protein conjugates and their intermediates |
WO2010075010A2 (en) | 2008-12-16 | 2010-07-01 | Genzyme Corporation | Oligosaccharide-protein conjugates |
CN105879047A (en) * | 2008-12-16 | 2016-08-24 | 建新公司 | Oligosaccharide-protein conjugates |
US10464962B2 (en) | 2008-12-16 | 2019-11-05 | Genzyme Corporation | Oligosaccharide-protein conjugates |
US9493498B2 (en) | 2008-12-16 | 2016-11-15 | Genzyme Corporation | Oligosaccharide-protein conjugates |
EP2465542A1 (en) | 2008-12-16 | 2012-06-20 | Genzyme Corporation | Oligosaccharide-protein conjugates |
JP2012512313A (en) * | 2008-12-16 | 2012-05-31 | ジェンザイム・コーポレーション | Oligosaccharide-protein complex |
JP2021169467A (en) * | 2008-12-16 | 2021-10-28 | ジェンザイム・コーポレーション | Oligosaccharide-protein conjugates |
US11279725B2 (en) | 2008-12-16 | 2022-03-22 | Genzyme Corporation | Oligosaccharide-protein conjugates |
EP3608330A3 (en) * | 2008-12-16 | 2020-05-13 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
EP3608330A2 (en) | 2008-12-16 | 2020-02-12 | Genzyme Corporation | Synthetic intermediates for preparing oligosaccharide-protein conjugates |
JP2014139204A (en) * | 2008-12-16 | 2014-07-31 | Genzyme Corp | Oligosaccharide-protein conjugates |
JP2019112444A (en) * | 2008-12-16 | 2019-07-11 | ジェンザイム・コーポレーション | Oligosaccharide-protein conjugates |
CN102369023A (en) * | 2008-12-16 | 2012-03-07 | 建新公司 | Oligosaccharide-protein conjugates |
JP2016113626A (en) * | 2009-07-27 | 2016-06-23 | リポクセン テクノロジーズ リミテッド | Glycopolysialylation of non-blood coagulation protein |
JP2018024882A (en) * | 2009-07-27 | 2018-02-15 | リポクセン テクノロジーズ リミテッド | Glycopolysialylation of non-blood coagulation protein |
JP2020037701A (en) * | 2009-07-27 | 2020-03-12 | バクサルタ インコーポレイテッド | Glycopolysialylation of non-blood coagulation protein |
US9795683B2 (en) | 2009-07-27 | 2017-10-24 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
US10772968B2 (en) | 2009-07-27 | 2020-09-15 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
JP2022058911A (en) * | 2009-07-27 | 2022-04-12 | バクサルタ インコーポレイテッド | Glycopolysialylation of non-blood coagulation protein |
JP2013500375A (en) * | 2009-07-27 | 2013-01-07 | リポクセン テクノロジーズ リミテッド | Glycopolysial oxidation of non-blood clotting proteins |
US10280414B2 (en) | 2009-11-17 | 2019-05-07 | Protalix Ltd. | Stabilized α-galactosidase and uses thereof |
US10870842B2 (en) | 2009-11-17 | 2020-12-22 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
US9708595B2 (en) | 2009-11-17 | 2017-07-18 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
US9194011B2 (en) | 2009-11-17 | 2015-11-24 | Protalix Ltd. | Stabilized alpha-galactosidase and uses thereof |
US9732333B2 (en) | 2011-01-20 | 2017-08-15 | Protalix Ltd. | Nucleic acid construct for expression of alpha-galactosidase in plants and plant cells |
US11103596B2 (en) | 2015-05-11 | 2021-08-31 | Ucl Business Plc | Fabry disease gene therapy |
WO2021156792A1 (en) | 2020-02-07 | 2021-08-12 | Novartis Ag | Targeted plasma protein degradation |
WO2021159092A1 (en) | 2020-02-08 | 2021-08-12 | Genzyme Corporation | Compositions and methods for treating pompe disease |
WO2021257409A1 (en) | 2020-06-14 | 2021-12-23 | Genzyme Corporation | Compositions and methods for treating late-onset pompe disease |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10907142B2 (en) | Oligosaccharides comprising an aminooxy group and conjugates thereof | |
ES2534056T3 (en) | Oligosaccharide-protein conjugates | |
WO2008089339A2 (en) | Oligosaccharide conjugates for cellular targeting |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200880007680.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 08727910 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 199925 Country of ref document: IL Ref document number: 2008727910 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2675968 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009546533 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12523631 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 222792 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 243117 Country of ref document: IL |